We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Allergy & Immunology

Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective

MedXY Editorial Team•Sep 22, 2026•Allergy & Immunology
dupilumabCT 影像mucus plugsasthmalung function

Highlight

  • Dupilumab significantly reduces total mucus plug number and volume in moderate to severe asthma patients as seen on CT imaging.
  • Individual mucus plugs resolve more frequently and new plug formation is markedly decreased following dupilumab treatment compared to controls.
  • Radiodensity of persistent and new mucus plugs exhibits a notable decrease post-dupilumab, implying qualitative changes in mucus composition.
  • Improvements in mucus burden correspond with enhanced lung function metrics, including FEV1 and ventilation assessed by 129Xe MRI.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evolving Impact of Inhaled Antibiotics on Lung Function in Cystic Fibrosis During the CFTR-Modulator EraThis analysis of U.S. CF Foundation registry data reveals that inhaled antibiotics confer lung function benefits primarily in chronic Pseudomonas aeruginosa infections, but their treatment benefit has declined with CFTR modulator use. RisksSep 27, 2026Mixed Mucus Plug-Emphysema Subtype and Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A Quantitative CT Phenotyping ApproachQuantitative CT-defined mucus plugs combined with emphysema severity stratify COPD patients into distinct subtypes that predict risk of acute exacerbations, enabling personalized risk assessment and targeted preventive strategies.Sep 25, 2026Quantitative CT-Based Mixed Mucus Plug-Emphysema Phenotyping Predicts Exacerbation Risk in COPD: Integrating Imaging Biomarkers for Precision MedicineThis review synthesizes recent evidence on quantitative CT markers of mucus plugging and emphysema in COPD, highlighting their combined impact on acute exacerbation risk and clinical heterogeneity, and discusses implications for personalizeSep 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized TrialThis article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emerSep 18, 2026
From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma ManagementThis review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.Sep 17, 2026
Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 AnalysisDupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.Sep 12, 2026